IL-17A in Psoriasis and Beyond: Cardiovascular and Metabolic Implications
Interleukin 17A (IL-17A) is one of the currently known six members of the IL-17 cytokine family and is implicated in immune responses to infectious pathogens and in the pathogenesis of inflammatory autoimmune diseases like psoriasis. Psoriatic skin is characterized by high expression of IL-17A and I...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-01-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fimmu.2019.03096/full |
id |
doaj-da70aae957b34e6fb84039ae93698ecc |
---|---|
record_format |
Article |
spelling |
doaj-da70aae957b34e6fb84039ae93698ecc2020-11-25T03:22:50ZengFrontiers Media S.A.Frontiers in Immunology1664-32242020-01-011010.3389/fimmu.2019.03096496613IL-17A in Psoriasis and Beyond: Cardiovascular and Metabolic ImplicationsEsther von Stebut0Wolf-Henning Boehncke1Wolf-Henning Boehncke2Kamran Ghoreschi3Tommaso Gori4Tommaso Gori5Ziya Kaya6Diamant Thaci7Andreas Schäffler8Department of Dermatology, University of Cologne, Cologne, GermanyDivision of Dermatology and Venereology, Geneva University Hospitals, Geneva, SwitzerlandDepartment of Pathology and Immunology, Faculty of Medicine, University de Geneva, Geneva, SwitzerlandDepartment of Dermatology, Venereology and Allergology, Charité—Universitätsmedizin Berlin, Berlin, GermanyCenter of Cardiology—Cardiology I, University Medical Center Mainz, Mainz, GermanyGerman Center for Cardiovascular Research, University Center Mainz, Mainz, GermanyDepartment of Internal Medicine III, University of Heidelberg, Heidelberg, GermanyInstitute and Comprehensive Center of Inflammation Medicine, University of Lübeck, Lübeck, GermanyDepartment of Internal Medicine III, Giessen University Hospital, Giessen, GermanyInterleukin 17A (IL-17A) is one of the currently known six members of the IL-17 cytokine family and is implicated in immune responses to infectious pathogens and in the pathogenesis of inflammatory autoimmune diseases like psoriasis. Psoriatic skin is characterized by high expression of IL-17A and IL-17F, which act on immune and non-immune cell types and strongly contribute to tissue inflammation. In psoriatic lesions, IL-17A, IL-17E, and IL-17F are involved in neutrophil accumulation, followed by the formation of epidermal micro abscesses. IL-17A together with other Th17 cytokines also upregulates the production of several chemokines that are implicated in psoriasis pathogenesis. IL17A-targeting antibodies show an impressive clinical efficacy in patients with psoriasis. Studies have reported an improvement of at least 75% as measured by the psoriasis area and severity index (PASI) in >80% of patients treated with anti-IL-17A therapy. Psoriasis skin manifestations, cardiovascular as well as metabolic disease in psoriasis appear to share pathogenic mechanisms evolving around IL-17A and its proinflammatory role. Thus, anti-IL-17A therapy not only improves skin manifestations of psoriasis, but also cardiovascular inflammation as well as metabolic factors and different domains of psoriatic arthritis (PsA) including peripheral arthritis, enthesitis, dactylitis, and axial involvement. This review summarizes the biological role of IL-17A, before reviewing currently available data on its role in the physiology and pathophysiology of the skin, as well as the cardiovascular and the metabolic system. In conclusion, clinical recommendations for patients with moderate to severe psoriasis based on the current available data are given.https://www.frontiersin.org/article/10.3389/fimmu.2019.03096/fullIL-17Apsoriasiscomorbiditiescardiovasculardiabetes |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Esther von Stebut Wolf-Henning Boehncke Wolf-Henning Boehncke Kamran Ghoreschi Tommaso Gori Tommaso Gori Ziya Kaya Diamant Thaci Andreas Schäffler |
spellingShingle |
Esther von Stebut Wolf-Henning Boehncke Wolf-Henning Boehncke Kamran Ghoreschi Tommaso Gori Tommaso Gori Ziya Kaya Diamant Thaci Andreas Schäffler IL-17A in Psoriasis and Beyond: Cardiovascular and Metabolic Implications Frontiers in Immunology IL-17A psoriasis comorbidities cardiovascular diabetes |
author_facet |
Esther von Stebut Wolf-Henning Boehncke Wolf-Henning Boehncke Kamran Ghoreschi Tommaso Gori Tommaso Gori Ziya Kaya Diamant Thaci Andreas Schäffler |
author_sort |
Esther von Stebut |
title |
IL-17A in Psoriasis and Beyond: Cardiovascular and Metabolic Implications |
title_short |
IL-17A in Psoriasis and Beyond: Cardiovascular and Metabolic Implications |
title_full |
IL-17A in Psoriasis and Beyond: Cardiovascular and Metabolic Implications |
title_fullStr |
IL-17A in Psoriasis and Beyond: Cardiovascular and Metabolic Implications |
title_full_unstemmed |
IL-17A in Psoriasis and Beyond: Cardiovascular and Metabolic Implications |
title_sort |
il-17a in psoriasis and beyond: cardiovascular and metabolic implications |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Immunology |
issn |
1664-3224 |
publishDate |
2020-01-01 |
description |
Interleukin 17A (IL-17A) is one of the currently known six members of the IL-17 cytokine family and is implicated in immune responses to infectious pathogens and in the pathogenesis of inflammatory autoimmune diseases like psoriasis. Psoriatic skin is characterized by high expression of IL-17A and IL-17F, which act on immune and non-immune cell types and strongly contribute to tissue inflammation. In psoriatic lesions, IL-17A, IL-17E, and IL-17F are involved in neutrophil accumulation, followed by the formation of epidermal micro abscesses. IL-17A together with other Th17 cytokines also upregulates the production of several chemokines that are implicated in psoriasis pathogenesis. IL17A-targeting antibodies show an impressive clinical efficacy in patients with psoriasis. Studies have reported an improvement of at least 75% as measured by the psoriasis area and severity index (PASI) in >80% of patients treated with anti-IL-17A therapy. Psoriasis skin manifestations, cardiovascular as well as metabolic disease in psoriasis appear to share pathogenic mechanisms evolving around IL-17A and its proinflammatory role. Thus, anti-IL-17A therapy not only improves skin manifestations of psoriasis, but also cardiovascular inflammation as well as metabolic factors and different domains of psoriatic arthritis (PsA) including peripheral arthritis, enthesitis, dactylitis, and axial involvement. This review summarizes the biological role of IL-17A, before reviewing currently available data on its role in the physiology and pathophysiology of the skin, as well as the cardiovascular and the metabolic system. In conclusion, clinical recommendations for patients with moderate to severe psoriasis based on the current available data are given. |
topic |
IL-17A psoriasis comorbidities cardiovascular diabetes |
url |
https://www.frontiersin.org/article/10.3389/fimmu.2019.03096/full |
work_keys_str_mv |
AT esthervonstebut il17ainpsoriasisandbeyondcardiovascularandmetabolicimplications AT wolfhenningboehncke il17ainpsoriasisandbeyondcardiovascularandmetabolicimplications AT wolfhenningboehncke il17ainpsoriasisandbeyondcardiovascularandmetabolicimplications AT kamranghoreschi il17ainpsoriasisandbeyondcardiovascularandmetabolicimplications AT tommasogori il17ainpsoriasisandbeyondcardiovascularandmetabolicimplications AT tommasogori il17ainpsoriasisandbeyondcardiovascularandmetabolicimplications AT ziyakaya il17ainpsoriasisandbeyondcardiovascularandmetabolicimplications AT diamantthaci il17ainpsoriasisandbeyondcardiovascularandmetabolicimplications AT andreasschaffler il17ainpsoriasisandbeyondcardiovascularandmetabolicimplications |
_version_ |
1724609296715481088 |